This article is more than 5 years old. Information may no longer be current.
Atezolizumab plus chemotherapy improves survival for small cell lung cancer
Click Here to Manage Email Alerts
A phase 3 trial assessing atezolizumab plus chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer met its co-primary endpoints of OS and PFS, according to the manufacturer.
The phase 3, multicenter, double-blind IMpower133 study assessed atezolizumab (Tecentriq, Genentech) — a PD-L1 monoclonal antibody — plus chemotherapy (carboplatin and etoposide) among 403 patients with extensive-stage small cell lung cancer compared with chemotherapy alone.
PFS as determined by the investigator using RECIST v1.1 and OS in the intention-to-treat population served as the co-primary endpoints.
The manufacturer today announced the combination of atezolizumab plus chemotherapy improved PFS and OS compared with chemotherapy alone.
Full results will be presented at an upcoming medical meeting.
“These are the first positive phase 3 survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer, a particularly difficult-to-treat type of disease,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a press release. “The clinically meaningful results from the IMpower133 study add to the growing body of evidence demonstrating that Tecentriq-based combinations may be an effective treatment for different types of advanced lung cancer. We look forward to working with health authorities globally to bring this potential treatment option to people with this type of disease as soon as possible.”
The safety profile of atezolizumab plus chemotherapy appeared consistent with the known profiles of the individual medicines. Researchers observed no new safety signals.
Atezolizumab is indicated for the treatment of certain patients with urothelial carcinoma and a subset of patients with non-small cell lung cancer.